Popoviciu L, Corfariu O
Br J Clin Pharmacol. 1983;16 Suppl 1(Suppl 1):97S-102S. doi: 10.1111/j.1365-2125.1983.tb02278.x.
Midazolam, in an oral dose of 15 mg, and placebo were administered to 15 children aged 6-15 years in treatment of night terrors. After an initial adaptation night, the patients received placebo for 2 nights, followed by 15 mg midazolam for 2 nights and placebo again on the final 2 nights. Eight-hour nocturnal polygraphic recordings were made after the administration of both placebo and midazolam. The patients were continuously monitored by means of closed circuit infra-red television. Ten of the patients manifested simple episodes while five had attacks associated with motor automatisms and EEG anomalies. The total sleep time was lengthened by midazolam in most of the children; sleep architecture was favourably modified, mainly in terms of the amount and proportion of REM sleep (accompanied by dreams) and stage 2 sleep. Night terrors were eliminated by midazolam in all except one patient. REM sleep latency also decreased as did the number of nocturnal arousals (clinical and/or EEG). In the five cases with a background of organic cerebral disorders, the EEG anomalies and these attacks were suppressed by midazolam especially during the first sleep cycles. Patients' subjective assessment of the quality of sleep was favourable. Midazolam was well tolerated with no side-effects.
对15名6至15岁的儿童口服15毫克咪达唑仑和安慰剂，用于治疗夜惊。在经过最初的适应期一晚后，患者服用安慰剂2晚，接着服用15毫克咪达唑仑2晚，最后2晚再次服用安慰剂。在服用安慰剂和咪达唑仑后均进行了8小时的夜间多导睡眠图记录。通过闭路红外电视对患者进行持续监测。10名患者表现为单纯发作，5名患者的发作伴有运动自动症和脑电图异常。大多数儿童服用咪达唑仑后总睡眠时间延长；睡眠结构得到有利改善，主要体现在快速眼动睡眠（伴有梦境）和第二阶段睡眠的时长及比例方面。除一名患者外，咪达唑仑消除了所有患者的夜惊。快速眼动睡眠潜伏期以及夜间觉醒次数（临床和/或脑电图）也有所减少。在5例有器质性脑疾病背景的病例中，咪达唑仑尤其在首个睡眠周期抑制了脑电图异常和这些发作。患者对睡眠质量的主观评价良好。咪达唑仑耐受性良好，无副作用。
